Currently the FDA has approved 3 GLP-1 RA s for the treatment of obesity: liraglutide, semaglutide, and tirzepatide (the latter is a GLP-1/glucose-dependent insulinotropic polypeptide [GIP] dual agonist). The gene discussed is GIP; the disease is obesity disorder.